Effect of recombinant human growth hormone therapy in prepuberty children with idiopathic short stature and analysis of the influencing factors.
- LIAN Qun,LI Ling-li.
Author information
+
History
+
Abstract
Objective To observe growth velocity and influencing factors for first-year of recombinant human growth hormone(rhGH)in treating prepuberty children with idiopathic short stature(ISS). Methods Forty-two prepubertal ISS children were treated with rhGH for at least one year.The relationships between gender,age at baseline,height standard deviation score pretreatment,Body Mass Index standard deviation score pretreatment,height standard deviation score of father,height standard deviation score of mother,growth velocity pretreatment,bone age pretreatment and the first year growth velocity were analyzed with correlation analysis. Results rhGH treatment improved all the 42 patients' the first year GV of ISS children in this study.Age at baseline is the independent influence factor on the first year GV. Conclusion rhGH-Treatment for ISS should be performed as young as possible.
Key words
idiopathic short stature / recombinant human growth hormone / growth velocity / influence factors
{{custom_sec.title}}
{{custom_sec.title}}
References
[1] Consensus statement on the diagnosis and treatment of children with idiopathic short stature:a summary of the Growth Hormone Research Society,the Lawson Wilkins Pediatric Endocrine Society,and the European Society for Paediatric Endocrinology Workshop[J].Clin Endocrinol Metab,2008,93(11):4210-4217.
[2] 李辉.中国0~18岁儿童青少年生长图表[M].1版.上海:第二军医大学出版社,2009,12.
[3] Pedicelli S,Peschiaroli E,Violi E,et al.Controversies in the definition and treatment of idiopathic short stature(ISS)[J].Clin Res Pediatr Endo crinol,2009,1(3):105-115.
[4] Deodati A,Cianfarani S.Impact of growth hormone therapy on adult height of children with idiopathic short stature:systematic review[J].BMJ,2011,11:342.
[5] Ranke MB,Lindberg A,Price DA,et al.Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short stature[J].Horm Res,2007,68(2):53-62.
[6] Bakker B,Frane J,Anhalt H,et al.Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children[J].Clin Endocrinol Metab,2008,93(2):352-357.
[7] 武华红,李辉,孙淑英.重组人生长激素治疗特发性矮小12个月疗效评估[J].中国循证儿科杂志,2012,7(1):63-67.
[8] Ross J,Lee PA,Gut R,et al.Factors influencing the one-and two-year growth response in children treated with growth hormone:analysis from an observational study[J].Int J Pediatr Endocrinol,2010,4946-4956.
[2] 李辉.中国0~18岁儿童青少年生长图表[M].1版.上海:第二军医大学出版社,2009,12.
[3] Pedicelli S,Peschiaroli E,Violi E,et al.Controversies in the definition and treatment of idiopathic short stature(ISS)[J].Clin Res Pediatr Endo crinol,2009,1(3):105-115.
[4] Deodati A,Cianfarani S.Impact of growth hormone therapy on adult height of children with idiopathic short stature:systematic review[J].BMJ,2011,11:342.
[5] Ranke MB,Lindberg A,Price DA,et al.Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short stature[J].Horm Res,2007,68(2):53-62.
[6] Bakker B,Frane J,Anhalt H,et al.Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children[J].Clin Endocrinol Metab,2008,93(2):352-357.
[7] 武华红,李辉,孙淑英.重组人生长激素治疗特发性矮小12个月疗效评估[J].中国循证儿科杂志,2012,7(1):63-67.
[8] Ross J,Lee PA,Gut R,et al.Factors influencing the one-and two-year growth response in children treated with growth hormone:analysis from an observational study[J].Int J Pediatr Endocrinol,2010,4946-4956.
